PharmD Info

1. Rituxan

Company: Roche
2017 U.S. sales: $4.41 billion
Disease: Blood cancers, rheumatoid arthritis
Competition expected: Mid- to end-2018

2. Neulasta

Company: Amgen
2017 U.S. sales: $3.93 billion
Use: White blood cell booster
Competition expected: Mid-2018

3. Lyrica

Company: Pfizer
2017 U.S. sales: $3.46 billion
Disease: Nerve and muscle pain
Patent expiration: Dec. 30

4. Advair

Company: GlaxoSmithKline
2017 U.S. sales: $2.23 billion
Disease: Asthma and COPD
Competition expected: Mid- to end-2018

5. Xolair

Company: Roche/Novartis
2017 U.S. sales: $1.83 billion
Disease: Allergic asthma and chronic idiopathic urticaria
Patent expiration: 2018

6. Epogen/Procrit

Company: Amgen and Johnson & Johnson
2017 U.S. sales: $1.77 billion
Disease: Anemia
Competition expected: Unknown

7. Restasis

Company: Allergan
2017 U.S. sales: $1.41 billion
Disease: Dry eye
Competition expected: Between April and July of 2018

8. Cialis

Company: Eli Lilly
2017 U.S. sales: $1.359 billion
Disease: Erectile dysfunction
Patent expiration: Sept. 27

9. Sensipar

Company: Amgen
2017 U.S. sales: $1.347 billion
Use: Calcium reducer
Patent expiration: March 8

10. Zytiga

Company: Johnson & Johnson
2017 U.S. sales: $1.228 billion
Disease: Prostate cancer
Generics expected: October 2018